Our findings suggest cooperative mechanisms of MSI2 over-expression driven by HOXA proteins and strongly supports MSI2 as a prognostic marker and a candidate in target treatment of CML. Here, MSI2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.